Related Experiment Video
Updated: Aug 14, 2026

Determining Optimal Cytotoxic Activity of Human Her2neu Specific CD8 T cells by Comparing the Cr51 Release Assay to the xCELLigence System
Published on: August 8, 2012
Expression of antigenic crossreactivity to RD114 p 30 protein in a human fibrosarcoma cell line
Abstract:
An antigen crossreacting with the 30,000-molecular-weight protein (p30) of the feline endogenous oncornavirus (RD114) was detected in a well-characterized human fibrosarcoma cell line, HT1080, by indirect immunofluorescence. Three antisera against RD114 p30 gave similar positive results, while two antisera prepared against simian sarcoma virus p30, one antiserum prepared against murine leukemia virus p30, and one antiserum prepared against feline leukemia virus p30 gave no immunofluorescence. The reactivity observed with the antiserum against RD114 p30 was detected in 10-40% of the cells at early passages and was no longer expressed by the forty-first subculture. The reactivity could be removed by adsorption of the antiserum with RD114-infected dog or human cells, but not by uninfected cells or by cells infected with an antigenically unrelated oncornavirus, feline leukemia virus. Neither complete virus particles nor reverse transcriptase (RNA-dependent DNA nucleotidyltransferase) activity was detected in the culture. These experiments suggest that the fibrosarcoma cell line is expressing an antigen related to the p30 protein of RD114 baboon endogenous virus group of oncornaviruses without producing complete virions.
Insights
A human fibrosarcoma cell line expresses an antigen related to feline endogenous oncornavirus RD114's p30 protein. This cross-reactivity was detected without evidence of complete virus production or reverse transcriptase activity.
Area of Science:
- Oncology
- Virology
- Molecular Biology
Background:
- Human fibrosarcoma cell lines are valuable models for studying cellular and viral interactions.
- Endogenous oncornaviruses, like feline endogenous oncornavirus (RD114), can integrate into host genomes and express viral proteins.
- The p30 protein is a major structural component of retroviral cores, making it a target for immunological detection.
Purpose of the Study:
- To investigate the presence of feline endogenous oncornavirus (RD114) p30 antigen in the HT1080 human fibrosarcoma cell line.
- To characterize the nature of the detected antigen and its relationship to RD114 p30.
- To determine if the expression of this antigen is associated with the production of infectious virions.
Main Methods:
- Indirect immunofluorescence assays were used to detect the p30 antigen.
- Antisera against RD114 p30 and other retroviral p30 proteins were employed for specificity testing.
- Adsorption experiments with infected and uninfected cells were performed to confirm antigenicity.
- Assays for complete virus particles and reverse transcriptase activity were conducted.
Main Results:
- An antigen cross-reactive with RD114 p30 was detected in HT1080 cells using specific antisera.
- This reactivity was observed in a subset of cells at early passages and diminished over time.
- The antigenicity was confirmed by adsorption with RD114-infected cells, but not with uninfected or feline leukemia virus-infected cells.
- No complete virus particles or reverse transcriptase activity were detected in the HT1080 cell cultures.
Conclusions:
- The HT1080 fibrosarcoma cell line expresses an antigen related to the RD114 baboon endogenous virus group p30 protein.
- This expression occurs without the production of complete virions or detectable reverse transcriptase activity.
- The findings suggest the presence of endogenous viral elements or expression of related antigens within the human fibrosarcoma cell line.
More Related Videos
10:13Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
Published on: May 6, 2019
05:21Assessing Antibody-dependent, Cell-mediated Cytotoxicity in Cancer Cells using Antibody-Dependent Cell-Mediated Cytotoxicity Reporter Bioassay
Published on: September 13, 2024